Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 1/20 | 0.72 |
| ▸ | RAB9A | P51151 | 6/20 | 0.65 |
| ▸ | NPC1 | O15118 | 5/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.60 |
| ▸ | TP53 | P04637 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28805447 | 0.86 | RAB9A (0.65) | CTSDRAB9ANPC1HPGDATM | |
| SCHEMBL4224402 | 0.84 | CTSD (0.74) | CTSDRAB9ANPC1HPGDTP53 | |
| SCHEMBL6618245 | 0.84 | CTSD (0.59) | CTSDRAB9ANPC1HPGDATM | |
| SCHEMBL1534502 | 0.84 | RAB9A (0.61) | RAB9ANPC1HPGDATML3MBTL1 | |
| SCHEMBL1437649 | 0.84 | RAB9A (0.61) | RAB9ANPC1HPGDATML3MBTL1 | |
| SCHEMBL27501780 | 0.84 | NPC1 (0.71) | CTSDRAB9ANPC1HPGDATM | |
| SCHEMBL295407 | 0.84 | CTSD (1.00) | CTSDRAB9ANPC1HPGDSMN1; SMN2 | |
| SCHEMBL30349208 | 0.84 | CTSD (1.00) | CTSDRAB9ANPC1HPGDSMN1; SMN2 | |
| SCHEMBL11632720 | 0.83 | NPC1 (0.55) | CTSDRAB9ANPC1HPGDATM | |
| SCHEMBL30686690 | 0.83 | HPGD (0.78) | RAB9ANPC1HPGDATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108623625-A | With active organic vanadium complex of para-insulin and preparation method thereof | 山东理工大学 | 2018-10-09 | — | — | CN | disclosed |
| CN-108264453-A | The synthetic method of pharmaceutical intermediate 3,5- dimethoxy benzaldehydes | 成都卡迪夫科技有限公司 | 2018-07-10 | — | — | CN | disclosed |
| EP-2124913-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| EP-2046336-A2 | 3-ARYL-6-ARYL-7H-[1,2,4]TRIAZOLO[3,4-b][1,3,4]THIADIAZINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | Cytovia, Inc. (US) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008077597-A1 | 1-AMINOMETHYL- L- PHENYL- CYCLOHEXANE DERIVATIVES AS DDP-IV INHIBITORS | NOVARTIS AG (CH) | 2008-07-03 | — | — | WO | disclosed |
| US-20080045514-A1 | 3-Aryl-6-aryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2008-02-21 | — | — | US | disclosed |
| WO-2008011045-A2 | 3-ARYL-6-ARYL-7H-[1,2,4]TRIAZOLO[3,4-b][1,3,4]THIADIAZINES AND ANALOGS AS ACTIVATORS OF CASPASES AND INDUCERS OF APOPTOSIS AND THE USE THEREOF | CYTOVIA, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| EP-1414804-A1 | ACYLSEMICARBAZIDES AND THEIR USE AS CYCLIN DEPENDENT KINASE (CDK) INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2004-05-06 | — | — | EP | disclosed |
| CN-1148357-C | Triazole and imidazole derivative | - | 2004-05-05 | — | — | CN | disclosed |
| EP-1070708-B1 | Triazole derivatives | HOFFMANN LA ROCHE (CH) | 2004-01-14 | — | — | EP | disclosed |
| WO-2002034721-A1 | ACYLSEMICARBAZIDES AND THEIR USE AS CYCLIN DEPENDENT KINASE (CDK) INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-05-02 | — | — | WO | disclosed |
| US-6265426-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | HOFFMANN-LA ROCHE INC. | 2001-07-24 | — | — | US | disclosed |
| CN-1281852-A | Triazole and imidazole derivative | HOFFMANN LA ROCHE (CH) | 2001-01-31 | — | — | CN | disclosed |
| EP-1070708-A1 | Triazole and imidazole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045514-A1 | 3-Aryl-6-aryl-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP3, CASP1, CASP2 | CTSD 2223/4885RAB9A 3132/4885NPC1 3262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.